Continuing Access to In-Home IVIG Act

The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to enactment of HR 7839, extension of the IVIG Demonstration project.

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Policies to enhance patient access to medicines in Medicare; Review of proposed rule regarding testing of Medicare part B prescription drug models; Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor; Proposals related to amending the protected classes in Medicare; Medicare payment proposals; H.R. 6218, S. 3457, Preserving Patient Access to Home Infusion Act - provisions related to home infusion payment; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - provisions related to Medicaid drug rebates; S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act - provisions related to prescription drug vial sizes and rebates; S. 2543, The Prescription Drug Pricing Reduction Act of 2019 - provisions related to lower prescription drug prices and transparency of pharmaceutical prices and transactions; H.R. 7839, Continuing Access to In-Home IVIG Act - provisions related to patient access; H.R.7783, S.4179, Plasma Donation Awareness Act - provisions related to plasma donation access;

Client expense: $410,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals. H.R.7839, Continuing Access to In-Home IVIG Act. Executive Order on Access to Affordable Life-saving Medications (E.O. 13937). Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938). Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939). Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948). Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944). Executive Order on An America-First Healthcare Plan (E.O. 13951). H.R.7783, Plasma Donation Awareness Act of 2020; S.4179, Plasma Donation Awareness Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 2279 and S. 2546, Safe Step Act; general issues pertaining to prescription drug costs; general issues pertaining to mental health; issues related to plasma-derived therapies for the treatment of COVID-19 patients; H.R. 4439, Creating Hope Reauthorization Act; H.R. 7839, Continuing Access to In- Home IVIG Act; Consolidated Appropriations Act of 2021, provision relating to extension of Medicare patient IVIG access demonstration project.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals that impact Medicare Part D. Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues related to H.R. 7839 Continuing Access to In Home IVIG Act. H.R. 7659/S. 4840, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Medicare prescription drug benefit; government negotiation/rebates for Medicare Part D; discounts in the Medicare Part D donut hole and drug company payments in the catastrophic benefit; coverage and payment policies for Medicare Part B prescription drugs; international reference pricing proposals (S. 977); and the "most favored nation" pricing. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 7839, the Continuing Access to In-Home IVIG Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Payment policies for Medicare Part B prescription drugs; Medicare drug coverage and payment policies for plasma protein products. Medicare coverage and payment for home infusion of drugs generally and during the COVID-19 public health emergency. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 7839, the Continuing Access to In-Home IVIG Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 7839, Continuing Access to In-Home IVIG Act. Monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act, including access to IVIG and telehealth. Issues related to Medicare Advantage plans.

Client expense: Not reported · Firm income: $60,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Medicare home infusion coverage and reimbursement Prescription Drug Pricing and Transparency Issues HR 7839: Continuing Access to In-Home IVIG Act

Client expense: $80,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R. 7839 - Continuing Access to In-Home IVIG Act; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Policies to enhance patient access to medicines in Medicare; Review of proposed rule regarding testing of Medicare part B prescription drug models; Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor; Proposals related to amending the protected classes in Medicare; Medicare payment proposals; S. 62, The Empowering Medicare Seniors to Negotiate Drug Prices Act - provisions related to Part D and drug pricing negotiation; S. 99, H.R. 448, The Medicare Drug Price Negotiation Act - provisions related to Part D and drug pricing negotiation; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 - provisions related to Part D and drug pricing negotiation; S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act - provisions related to prescription drug vial sizes and rebates; H.R. 4649 Capping Drug Costs for Seniors Act - provisions related to Part D redesign; H.R. 7839, Continuing Access to In-Home IVIG Act - provisions related to patient access; H.R.7783, S.4179, Plasma Donation Awareness Act - provisions related to plasma donation access; H.R. 6218, S. 3457, Preserving Patient Access to Home Infusion Act - provisions related to home infusion payment;

Client expense: $1,160,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800 / H.R. 925 the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) -Issues related to H.R. 6810, the Health Care Protection Act, and H.R. 6514, the Worker Health Coverage Protection Act, and S. 4329, the Continuous Health Coverage for Workers Act. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. -H.R. 6561/S. 4440 - Improving Social Determinants of Health Act of 2020. -Healthcare, Economic Assistance, Liability, And Schools (HEALS Act), including S. 4317 the Safe to Work Act; S. 4318, the American Workers, Families, And Employers Assistance Act; S. 4321, the Continuing Small Business Recovery And Paycheck Protection Program Act; S. 4322, the Safely Back To School And Back To Work Act; and S. 4323, Time to Rescue United States Trusts Act of 2020 (TRUST Act). -Issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act. -Issues related to H.R. 8308, to amend the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person, and for other purposes.

Client expense: $1,690,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of

Issues related to Medicare Advantage and issues related to price transparency. Issues related to the Executive Order on Lowering Drug Prices by Putting America First. Issues related to H.R. 7839, Continuing Access to In Home IVIG Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Proposals that impact Medicare Part D. Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues related to H.R. 7839 Continuing Access to In Home IVIG Act

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to Medicare Advantage and issues related to price transparency. Issues related to the Executive Order on Lowering Drug Prices by Putting America First. Issues related to H.R. 7839, Continuing Access to In Home IVIG Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 7839 - Continuing Access to In-Home IVIG Act; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act"), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; Medicare prescription drug benefit; government negotiation/rebates for Medicare Part D; discounts in the Medicare Part D donut hole and drug company payments in the catastrophic benefit; coverage and payment policies for Medicare Part B prescription drugs; international reference pricing proposals (S. 977); and the "most favored nation" pricing. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 7839, the Continuing Access to In-Home IVIG Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Payment policies for Medicare Part B prescription drugs; Medicare drug coverage and payment policies for plasma protein products. Medicare coverage and payment for home infusion of drugs generally and during the COVID-19 public health emergency. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 7839, the Continuing Access to In-Home IVIG Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. Issues related to the Executive Order on Lowering Drug Prices by Putting America First. H.R. 7839, Continuing Access to In-Home IVIG Act.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to depression, mental health, opioid abuse, direct-to-consumer (DTC) advertising, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals. H.R.7839, Continuing Access to In-Home IVIG Act. Executive Order on Access to Affordable Life-saving Medications (E.O. 13937). Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938). Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939). Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948). Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944). Executive Order on An America-First Healthcare Plan (E.O. 13951).

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 2279 and S. 2546, Safe Step Act; general issues pertaining to prescription drug costs; general issues related to drug manufacturing; issues related to plasma-derived therapies for the treatment of COVID-19 patients; H.R. 4439, Creating Hope Reauthorization Act; H.R. 7839, Continuing Access to In-Home IVIG Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE